Evidence map›Paper›PMID 38991010›Full record

ArticleAmerican journal of physiology. Renal physiology2024

Role of the CDKL1-SOX11 signaling axis in acute kidney injury.

Josie A Silvaroli, Gabriela V Martinez, Thitinee Vanichapol, Alan J Davidson, Diana Zepeda-Orozco, Navjot S Pabla, Ji Young Kim

Abstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Josie A SilvaroliDivision of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, United States.ORCID 0000-0002-4505-3670
Gabriela V MartinezKidney and Urinary Tract Research Center, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, United States.
Thitinee VanichapolDepartment of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.ORCID 0000-0002-6647-7608
Alan J DavidsonDepartment of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand.ORCID 0000-0002-5732-1193
Diana Zepeda-OrozcoKidney and Urinary Tract Research Center, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, United States.ORCID 0000-0003-0671-4453
Navjot S PablaDivision of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, United States.
Ji Young KimDivision of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, United States.ORCID 0000-0002-3736-9050

Funding

Off target mechanisms of kinase inhibitor toxicitiesR01DK132230 · NIDDK · OHIO STATE UNIVERSITY · PI BAJWA, AMANDEEP, PABLA, NAVJOT · 2022 to 2025
$2.0M
American Heart Association (AHA) 900765HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) R01DK132230LouLou FoundationNIDDK NIH HHS R01 DK132230Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (The James)OSU | Graduate School, Ohio State University
6 · The paper itself

Abstract

The biology of the cyclin-dependent kinase-like (CDKL) kinase family remains enigmatic. Contrary to their nomenclature, CDKLs do not rely on cyclins for activation and are not involved in cell cycle regulation. Instead, they share structural similarities with mitogen-activated protein kinases and glycogen synthase kinase-3, although their specific functions and associated signaling pathways are still unknown. Previous studies have shown that the activation of CDKL5 kinase contributes to the development of acute kidney injury (AKI) by suppressing the protective SOX9-dependent transcriptional program in tubular epithelial cells. In the current study, we measured the functional activity of all five CDKL kinases and discovered that, in addition to CDKL5, CDKL1 is also activated in tubular epithelial cells during AKI. To explore the role of CDKL1, we generated a germline knockout mouse that exhibited no abnormalities under normal conditions. Notably, when these mice were challenged with bilateral ischemia-reperfusion and rhabdomyolysis, they were found to be protected from AKI. Further mechanistic investigations revealed that CDKL1 phosphorylates and destabilizes SOX11, contributing to tubular dysfunction. In summary, this study has unveiled a previously unknown CDKL1-SOX11 axis that drives tubular dysfunction during AKI.

Indexed as

Acute Kidney InjuryCyclin-Dependent KinasesSignal TransductionSOXC Transcription FactorsAnimalsDisease Models, AnimalEpithelial CellsMaleMiceMice, Inbred C57BLMice, KnockoutPhosphorylationProtein Serine-Threonine KinasesReperfusion InjuryRhabdomyolysisCyclin-Dependent KinasesProtein Serine-Threonine KinasesSox11 protein, mouseSOXC Transcription Factorsacute kidney injurycyclin-dependent kinase-like 1ischemiarenal tubular epithelial cellsrhabdomyolysis

Identifiers

PMID38991010
PMCPMC11460330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.